Compare ANIK & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIK | MCN |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.3M | 125.6M |
| IPO Year | 1996 | N/A |
| Metric | ANIK | MCN |
|---|---|---|
| Price | $12.69 | $6.08 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 140.9K | 80.8K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | ★ 32.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,907,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $5.16 |
| 52 Week High | $17.74 | $6.46 |
| Indicator | ANIK | MCN |
|---|---|---|
| Relative Strength Index (RSI) | 82.44 | 50.02 |
| Support Level | $10.62 | $5.99 |
| Resistance Level | $15.10 | $6.18 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 94.61 | 34.23 |
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.